scispace - formally typeset
D

Do Young Kim

Researcher at Yonsei University

Publications -  737
Citations -  18320

Do Young Kim is an academic researcher from Yonsei University. The author has contributed to research in topics: Hepatocellular carcinoma & Medicine. The author has an hindex of 58, co-authored 674 publications receiving 15091 citations. Previous affiliations of Do Young Kim include University of Ulsan & Fred Hutchinson Cancer Research Center.

Papers
More filters
Journal ArticleDOI

Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

TL;DR: PIVKA-II can be used as a tumor marker for the early detection of HCC in patients with chronic HBV infection, especially in combination with AFP.
Journal ArticleDOI

Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir

TL;DR: A new hepatocellular carcinoma risk prediction model, PAGE‐B, which includes age, gender and platelet count as constituent variables, is validated and compared with conventional risk prediction models in Asian chronic hepatitis B patients.
Journal ArticleDOI

Impact of spontaneous hepatocellular carcinoma rupture on recurrence pattern and long-term surgical outcomes after partial hepatectomy

TL;DR: Patients with spontaneously rupturing HCC with staged hepatectomy show comparable long-term survival and recurrence pattern as patients with non-ruptured HCC having similar tumor characteristics and liver functional status.
Journal ArticleDOI

Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma.

TL;DR: Elevated preoperative AFP and DCP levels were associated with a higher recurrence rate and shorter DFS in patients with HBV‐related HCC after curative resection, and may be a prognostic factor for future recurrence.
Journal ArticleDOI

Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size.

TL;DR: This study aims to evaluate clinical outcomes of patients with hepatocellular carcinoma who underwent transarterial chemoembolization (TACE) using drug‐eluting beads (DEB).